Clinical Scorecard: AMD incidence may be higher in lupus
At a Glance
Category
Detail
Condition
Age-related macular degeneration (AMD) incidence in adults with systemic lupus erythematosus (SLE)
Key Mechanisms
The study assessed incident dry and neovascular AMD; it did not establish a causal mechanism linking SLE or hydroxychloroquine exposure to AMD.
Target Population
Korean adults aged 45 years and older with incident SLE, compared with matched controls without SLE.
Care Setting
Retrospective population-based claims study; findings concern ophthalmic outcomes in people with SLE.
Key Highlights
Overall AMD incidence was 49.1 per 10,000 person-years among patients with SLE and 26.7 among controls.
Neovascular AMD incidence was 10.5 per 10,000 person-years in SLE and 3.3 in controls; dry AMD incidence was 38.6 and 23.4, respectively.
Treatment-defined severe SLE was not associated with statistically significantly higher incidence of overall, dry, or neovascular AMD than nonsevere SLE.
The SLE-control association with neovascular AMD persisted across hydroxychloroquine exposure-duration groups, but longer exposure was not significantly associated with higher neovascular AMD hazards in analyses restricted to SLE.
The retrospective claims-based design cannot establish causality; differential eye-examination frequency and unmeasured confounding may have affected findings.
Guideline-Based Recommendations
Diagnosis
Neovascular AMD identification required a diagnosis code and a copayment registration code indicating ophthalmologist-confirmed choroidal neovascularization.
Management
Monitoring & Follow-up
Risks
Patients with SLE had higher observed incidence of overall, dry, and neovascular AMD than matched controls.
The study authors cautioned that more frequent ophthalmic examinations, particularly during hydroxychloroquine treatment, could increase AMD detection.
The study did not establish a causal effect of SLE or hydroxychloroquine on AMD.
Patient & Prescribing Data
The cohort included 9,496 Korean patients aged 45 years and older with incident SLE from 2011 to 2020 and 28,488 matched controls; mean follow-up was 6.7 and 7 years, respectively.
Compared with controls, patients with SLE exposed to hydroxychloroquine for less than 5 years had about 2.7 times the likelihood of neovascular AMD, and those exposed for at least 5 years had about 4 times the likelihood. Within the SLE cohort, longer exposure was not significantly associated with higher neovascular AMD hazards; exposure duration was an imperfect marker of ophthalmic surveillance.
Clinical Best Practices
Interpret the reported associations as observational findings, not evidence that SLE or hydroxychloroquine causes AMD.
Consider the study's limitations when applying its findings: it lacked smoking, body mass index, family history, genetic susceptibility, retinal imaging, visual acuity, and detailed AMD severity or progression data.
Note that treatment-defined SLE severity was based on sustained intravenous cyclophosphamide or mycophenolate mofetil use for at least 6 months and did not directly measure disease activity.
The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.
